JP2013504328A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013504328A5 JP2013504328A5 JP2012528940A JP2012528940A JP2013504328A5 JP 2013504328 A5 JP2013504328 A5 JP 2013504328A5 JP 2012528940 A JP2012528940 A JP 2012528940A JP 2012528940 A JP2012528940 A JP 2012528940A JP 2013504328 A5 JP2013504328 A5 JP 2013504328A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- chimeric molecule
- acid residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 30
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 24
- 125000000539 amino acid group Chemical group 0.000 claims 20
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 15
- 239000004471 Glycine Chemical group 0.000 claims 15
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Chemical group OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 15
- 235000004279 alanine Nutrition 0.000 claims 15
- 150000007523 nucleic acids Chemical class 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 230000008685 targeting Effects 0.000 claims 12
- 239000001132 aluminium potassium sulphate Substances 0.000 claims 10
- 239000001194 polyoxyethylene (40) stearate Substances 0.000 claims 10
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 9
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 claims 5
- 150000001413 amino acids Chemical group 0.000 claims 5
- 101100321445 Arabidopsis thaliana ZHD3 gene Proteins 0.000 claims 4
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 4
- -1 CD79b Proteins 0.000 claims 4
- 102000000905 Cadherin Human genes 0.000 claims 4
- 108050007957 Cadherin Proteins 0.000 claims 4
- 102100032768 Complement receptor type 2 Human genes 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 4
- 102000001301 EGF receptor Human genes 0.000 claims 4
- 108060006698 EGF receptor Proteins 0.000 claims 4
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 4
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims 4
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 4
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 4
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 4
- 102000003735 Mesothelin Human genes 0.000 claims 4
- 108090000015 Mesothelin Proteins 0.000 claims 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 4
- 101710160107 Outer membrane protein A Proteins 0.000 claims 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 4
- 108010033576 Transferrin Receptors Proteins 0.000 claims 4
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims 4
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 4
- 239000003102 growth factor Substances 0.000 claims 4
- 230000010261 cell growth Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24162009P | 2009-09-11 | 2009-09-11 | |
| US61/241,620 | 2009-09-11 | ||
| PCT/US2010/048504 WO2011032022A1 (en) | 2009-09-11 | 2010-09-10 | Improved pseudomonas exotoxin a with reduced immunogenicity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013504328A JP2013504328A (ja) | 2013-02-07 |
| JP2013504328A5 true JP2013504328A5 (https=) | 2013-10-24 |
| JP5795765B2 JP5795765B2 (ja) | 2015-10-14 |
Family
ID=43446435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012528940A Expired - Fee Related JP5795765B2 (ja) | 2009-09-11 | 2010-09-10 | 低減した免疫原性を有する改良型シュードモナス（Ｐｓｅｕｄｏｍｏｎａｓ）外毒素Ａ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8936792B2 (https=) |
| EP (1) | EP2475398B1 (https=) |
| JP (1) | JP5795765B2 (https=) |
| CN (1) | CN102655882B (https=) |
| AU (1) | AU2010292069B2 (https=) |
| CA (1) | CA2773665C (https=) |
| ES (1) | ES2544805T3 (https=) |
| RU (1) | RU2012114005A (https=) |
| WO (1) | WO2011032022A1 (https=) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2372537T3 (es) * | 2005-07-29 | 2012-01-23 | The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services | Exotoxinas de pseudomonas mutadas con antigenicidad reducida. |
| US9623117B2 (en) * | 2011-04-04 | 2017-04-18 | Wisconsin Alumni Research Foundation | Method for selective targeting and entry of bacterial toxins to cells |
| EP2699603B1 (en) | 2011-04-19 | 2016-03-02 | The United States of America As Represented by the Secretary Department of Health and Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
| SG194787A1 (en) | 2011-05-06 | 2013-12-30 | Us Gov Health & Human Serv | Recombinant immunotoxin targeting mesothelin |
| KR20140033391A (ko) * | 2011-06-09 | 2014-03-18 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 면역원성이 보다 낮은 t 세포 및/또는 b 세포 에피토프를 갖는 슈도모나스 외독소 a |
| US8932586B2 (en) | 2011-09-06 | 2015-01-13 | Intrexon Corporation | Modified forms of Pseudomonas exotoxin A |
| WO2013039916A1 (en) | 2011-09-12 | 2013-03-21 | The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services | Compositions for and methods of treatment and enhanced detection of non-pituitary tumors |
| AU2012308591B2 (en) | 2011-09-16 | 2017-02-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pseudomonas exotoxin a with less immunogenic B cell epitopes |
| ES2654060T3 (es) | 2011-10-20 | 2018-02-12 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Receptores de antígenos quiméricos anti-CD22 |
| SG11201407972RA (en) | 2012-06-01 | 2015-01-29 | Us Health | High-affinity monoclonal antibodies to glypican-3 and use thereof |
| RU2684595C2 (ru) | 2012-07-04 | 2019-04-09 | Ф.Хоффманн-Ля Рош Аг | Ковалентно связанные конъюгаты антиген-антитело |
| EP2870180B1 (en) | 2012-07-04 | 2024-08-28 | F. Hoffmann-La Roche AG | Anti-biotin antibodies and methods of use |
| DK2869837T3 (en) | 2012-07-04 | 2016-09-26 | Hoffmann La Roche | Anti-theophylline antibodies and methods of use |
| EP3327037B1 (en) | 2012-08-21 | 2019-10-09 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Mesothelin domain-specific monoclonal antibodies and use thereof |
| CN104955845B (zh) | 2012-09-27 | 2018-11-16 | 美国政府(由卫生和人类服务部的部长所代表) | 间皮素抗体和引起有效的抗肿瘤活性的方法 |
| MA38165A1 (fr) | 2012-11-08 | 2018-07-31 | Hoffmann La Roche | Protéines de liaison à l'antigène her3 se liant à l'épingle à cheveux beta de her3 |
| CA2894908C (en) * | 2012-12-20 | 2022-07-12 | Medimmune, Llc | Methods of producing immunoconjugates |
| US9890369B2 (en) | 2013-06-20 | 2018-02-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor |
| WO2015051199A2 (en) * | 2013-10-06 | 2015-04-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified pseudomonas exotoxin a |
| CN105813654B (zh) | 2013-10-11 | 2019-05-31 | 美国政府(由卫生和人类服务部的部长所代表) | Tem8抗体及其用途 |
| WO2015069922A2 (en) | 2013-11-06 | 2015-05-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Alk antibodies, conjugates, and chimeric antigen receptors, and their use |
| AU2014368696A1 (en) | 2013-12-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Humanized anti-Tau(pS422) antibodies and methods of use |
| EP3089758B1 (en) | 2014-01-03 | 2021-01-27 | F.Hoffmann-La Roche Ag | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
| BR112016014945A2 (pt) | 2014-01-03 | 2018-01-23 | F. Hoffmann-La Roche Ag | conjugado, formulação farmacêutica e uso |
| CN105899540B (zh) | 2014-01-03 | 2020-02-07 | 豪夫迈·罗氏有限公司 | 双特异性抗-半抗原/抗-血脑屏障受体的抗体、其复合物及它们作为血脑屏障穿梭物的应用 |
| WO2015120058A2 (en) | 2014-02-05 | 2015-08-13 | Molecular Templates, Inc. | Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity |
| AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
| JP6811706B2 (ja) | 2014-07-31 | 2021-01-13 | ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー | Ｅｐｈａ４に対するヒトモノクローナル抗体及びそれらの使用 |
| WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
| WO2016207245A1 (en) | 2015-06-24 | 2016-12-29 | F. Hoffmann-La Roche Ag | Humanized anti-tau(ps422) antibodies and methods of use |
| CA3289997A1 (en) | 2015-09-20 | 2026-03-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal Antibodies Specific for Fibroblast Growth Factor Receptor 4 (FGFR4) and Methods of Their Use |
| CN106589131B (zh) * | 2015-10-19 | 2021-06-11 | 山东省妇幼保健院 | 融合蛋白4D5Fv-PE25及其制备方法和用途 |
| EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
| CN108473575B (zh) | 2015-11-13 | 2022-04-19 | 美国卫生和人力服务部 | 抗-bcma多肽和蛋白质 |
| WO2017196847A1 (en) | 2016-05-10 | 2017-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens |
| WO2017214182A1 (en) | 2016-06-07 | 2017-12-14 | The United States Of America. As Represented By The Secretary, Department Of Health & Human Services | Fully human antibody targeting pdi for cancer immunotherapy |
| EP3494135A1 (en) | 2016-08-02 | 2019-06-12 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof |
| AU2017382883B2 (en) | 2016-12-21 | 2024-07-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for FLT3 and uses thereof |
| WO2018213612A1 (en) | 2017-05-18 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin polypeptides and proteins |
| WO2018213064A1 (en) | 2017-05-19 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibody targeting tnfer2 for cancer immunotherapy |
| WO2019006280A1 (en) | 2017-06-30 | 2019-01-03 | Lentigen Technology, Inc. | HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE |
| WO2019005208A1 (en) | 2017-06-30 | 2019-01-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY |
| AU2018321825A1 (en) * | 2017-08-19 | 2020-03-05 | Ohio State Innovation Foundation | Novel peptide-based cancer imaging agents |
| US11795235B2 (en) | 2017-09-18 | 2023-10-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunotoxins with albumin binding domain |
| US11939377B2 (en) | 2018-07-12 | 2024-03-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Affinity matured CD22-specific monoclonal antibody and uses thereof |
| EP3833684A1 (en) | 2018-08-08 | 2021-06-16 | The United States of America, as represented by the Secretary, Department of Health and Human Services | High affinity monoclonal antibodies targeting glypican-2 and uses thereof |
| CN109517070A (zh) * | 2018-11-07 | 2019-03-26 | 南京卡提医学科技有限公司 | 嵌合抗原受体DAP12-T2A-CD8α-MSLN scFv-TREM1及其用途 |
| CA3125484A1 (en) | 2019-01-08 | 2020-07-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cross-species single domain antibodies targeting mesothelin for treating solid tumors |
| US12122843B2 (en) | 2019-01-22 | 2024-10-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-1 and methods of use |
| WO2021003297A1 (en) | 2019-07-02 | 2021-01-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind egfrviii and their use |
| CA3156761A1 (en) | 2019-10-22 | 2021-04-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors |
| WO2021097289A1 (en) | 2019-11-15 | 2021-05-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pegylated recombinant immunotoxins |
| US20230391852A1 (en) | 2020-10-26 | 2023-12-07 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting sars coronavirus spike protein and uses thereof |
| WO2022109053A1 (en) | 2020-11-18 | 2022-05-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tyrosyl-lock peptides |
| WO2022135441A1 (zh) | 2020-12-22 | 2022-06-30 | 江苏恒瑞医药股份有限公司 | 抗il-4r抗体或其抗原结合片段的复合物及医药用途 |
| WO2022232612A1 (en) | 2021-04-29 | 2022-11-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Lassa virus-specific nanobodies and methods of their use |
| US20240270851A1 (en) | 2021-06-09 | 2024-08-15 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Cross species single domain antibodies targeting pd-l1 for treating solid tumors |
| WO2023076881A1 (en) | 2021-10-26 | 2023-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein |
| WO2023114980A1 (en) | 2021-12-17 | 2023-06-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors |
| US20260070960A1 (en) | 2022-09-01 | 2026-03-12 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes |
| WO2024238346A1 (en) | 2023-05-12 | 2024-11-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies that specifically bind the s2 subunit of sars-cov-2 spike protein and compositions and uses thereof |
| WO2025014896A1 (en) | 2023-07-07 | 2025-01-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Humanized 40h3 antibody |
| AU2024295016A1 (en) | 2023-07-20 | 2026-02-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors |
| WO2025106427A1 (en) | 2023-11-14 | 2025-05-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv) |
| WO2025171238A1 (en) | 2024-02-07 | 2025-08-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4892827A (en) | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5242824A (en) | 1988-12-22 | 1993-09-07 | Oncogen | Monoclonal antibody to human carcinomas |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| DK0531434T3 (da) | 1990-05-11 | 2000-01-31 | Us Health | Forbedrede Pseudomonas-exotoksiner med lav dyretoksicitet og høj cytocidal aktivitet |
| US5889157A (en) | 1990-10-12 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Humanized B3 antibody fragments, fusion proteins, and uses thereof |
| US5981726A (en) | 1990-10-12 | 1999-11-09 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and mutationally stabilized tumor-specific B1, B3 and B5 antibody fragments; immunotoxic fusion proteins; and uses thereof |
| US5846535A (en) | 1990-10-12 | 1998-12-08 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for reducing tumor cell growth by using antibodies with broad tumor reactivity and limited normal tissue reactivity |
| US5608039A (en) | 1990-10-12 | 1997-03-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Single chain B3 antibody fusion proteins and their uses |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| DE69311538D1 (de) | 1992-03-12 | 1997-07-17 | Alkermes Inc | Acth enthaltende mikrokugeln mit gesteuerter abgabe |
| WO1993025690A1 (en) | 1992-06-18 | 1993-12-23 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Recombinant pseudomonas exotoxin with increased activity |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US5686578A (en) | 1994-08-05 | 1997-11-11 | Immunomedics, Inc. | Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype |
| US5888773A (en) | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
| US6518061B1 (en) | 1995-03-15 | 2003-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
| ATE254931T1 (de) | 1996-01-05 | 2003-12-15 | Us Gov Health & Human Serv | Mesothelinantigen, verfahren und testsatz zur targetierung |
| US7541034B1 (en) | 1997-03-20 | 2009-06-02 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors |
| JP2001522241A (ja) | 1997-04-10 | 2001-11-13 | ロイヤル ネザーランズ アカデミー オブ アーツ アンド サイエンシズ | 診断方法および試薬 |
| US6809184B1 (en) | 1997-12-01 | 2004-10-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
| US6296843B1 (en) | 1998-04-03 | 2001-10-02 | The Penn State Research Foundation | Mutagenized IL 13-based chimeric molecules |
| EP2011801A1 (en) | 1999-05-27 | 2009-01-07 | Government of the United States as represented by the Secretary, Department of Health and Human Services | Immunoconjugates having high binding affinity |
| EP1263785A2 (en) | 1999-11-11 | 2002-12-11 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Mutated il-13 molecules and their uses |
| AU2002226930A1 (en) | 2000-11-17 | 2002-05-27 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the fv to lower the isoelectric point |
| US7355012B2 (en) | 2001-09-26 | 2008-04-08 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells |
| EA200400658A1 (ru) | 2001-11-09 | 2004-10-28 | Неофарм, Инк. | Способ лечения опухолей, экспрессирующих рецептор для ил-13 (варианты) |
| AU2003239248A1 (en) | 2002-06-07 | 2003-12-22 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And | Anti-cd30 stalk and anti-cd30 antibodies suitable for use in immunotoxins |
| US7982011B2 (en) | 2003-11-25 | 2011-07-19 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mutated anti-cd22 antibodies and immunoconjugates |
| ES2372537T3 (es) | 2005-07-29 | 2012-01-23 | The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services | Exotoxinas de pseudomonas mutadas con antigenicidad reducida. |
| WO2009032954A1 (en) | 2007-09-04 | 2009-03-12 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity |
-
2010
- 2010-09-10 ES ES10755283.8T patent/ES2544805T3/es active Active
- 2010-09-10 JP JP2012528940A patent/JP5795765B2/ja not_active Expired - Fee Related
- 2010-09-10 US US13/395,422 patent/US8936792B2/en active Active
- 2010-09-10 CA CA2773665A patent/CA2773665C/en active Active
- 2010-09-10 RU RU2012114005/10A patent/RU2012114005A/ru not_active Application Discontinuation
- 2010-09-10 CN CN201080049559.3A patent/CN102655882B/zh not_active Expired - Fee Related
- 2010-09-10 EP EP20100755283 patent/EP2475398B1/en active Active
- 2010-09-10 AU AU2010292069A patent/AU2010292069B2/en active Active
- 2010-09-10 WO PCT/US2010/048504 patent/WO2011032022A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013504328A5 (https=) | ||
| RU2012114005A (ru) | Усовершенствованный экзотоксин а pseudomonas со сниженной иммуногенностью | |
| JP2009225799A5 (https=) | ||
| JP2011036254A5 (https=) | ||
| JP2014506120A5 (https=) | ||
| JP2019500891A5 (https=) | ||
| JP2014522850A5 (https=) | ||
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| IL265179B1 (en) | Antibodies against PD-1 (CD27) | |
| HRP20161211T1 (hr) | Bispecifična antitijela protiv cd3-epsilon i bcma | |
| JP2011517447A5 (https=) | ||
| SI2753646T1 (en) | Anti-CD40 antibodies, uses and methods | |
| HRP20201747T1 (hr) | Bispecifične antigen vezujuće molekule koje aktiviraju t stanice, protiv folr1 i cd3 | |
| JP2020508655A5 (https=) | ||
| RU2013148919A (ru) | Рекомбинантный иммунотоксин, нацеленный на мезотелин | |
| JP2019505564A5 (https=) | ||
| FI3322727T3 (fi) | Humanisoituja tai kimeerisiä CD3-vasta-aineita | |
| JP2014515921A5 (https=) | ||
| JP2013519364A5 (https=) | ||
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| HRP20201375T1 (hr) | ANTI-BCMA ANTITIJELA, BISPECIFIČNI ANTIGEN VEŽUĆE MOLEKULE KOJE SE VEŽU ZA BCMA i CD3, I NJIHOVE UPOTREBE | |
| JP2017149720A5 (https=) | ||
| JP2010533498A5 (https=) | ||
| HRP20131215T1 (hr) | Antagonistiäśka humana monoklonska protutijela specifiäśna za humane slabe epitope | |
| JP2017504578A5 (https=) |